As per the terms of the deal, AstraZeneca received $250m from Cheplapharm. Credit: Nancy1007.

AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to German pharmaceutical firm Cheplapharm Arzneimittel.

A prescription medicine, Atacand is approved for treating heart failure (HF) and hypertension.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Atacand Plus is a fixed-dose blend of candesartan cilexetil and hydrochlorothiazide and is approved for treating hypertension.

Developed in partnership with Takeda Pharmaceutical, Atacand was co-marketed by the companies in certain counties while each firm had the exclusive rights to it in some countries.

Under the deal, AstraZeneca received $250m from Cheplapharm.

In addition, the company will get further non-contingent payments of around $150m during the first half of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In October, AstraZeneca agreed to sell the commercial rights to Atacand and Atacand Plus in around 70 countries to Cheplapharm for $400m.

Separately, Takeda Pharmaceutical has completed the sale of a portfolio of select prescription products to Cheplapharm for $562m.

The portfolio comprises 16 prescription pharmaceutical products sold mainly in Europe, part of the company’s Europe and Canada business unit.

In September, Takeda signed an agreement to divest a portfolio of certain non-core assets sold primarily in Europe and Canada to Cheplapharm.

The divested portfolio includes non-core prescription pharmaceuticals across various therapeutic areas, including cardiovascular / metabolic and anti-inflammatory products along with Calcium.

These products are not part of Takeda’s five core business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience.

Takeda noted that it is focused on carrying out its long-term growth strategy to enhance business mix around our key areas and streamlining operations by providing patients with novel therapies in these areas.